CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

Income Statement

Follow revenue through to earnings.

Revenue

$76.20M

FY 2025 · Annual

-44.8% YoY

Operating Income

-$22.36M

FY 2025 · Annual

Net Income

-$17.37M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CTMX Earnings Waterfall · TTM

NASDAQ:CTMX · Revenue to Net Income

Key Ratios

EPS$-0.36
Gross Margin99.4%
Net Margin-1104.0%
P/E Ratio-125.8
P/S Ratio319.7

Analysis

$35.5M of revenue converted into -$59.1M of net income for the selected period. Gross margin is 99.4% and net margin is -1104.0%, showing how much revenue survives after costs and taxes. EPS is $-0.36, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 28, 2026
4/A4/A filingOct 16, 2026

How much revenue does CTMX generate?

CytomX Therapeutics, Inc. (CTMX) reported $76.20M of revenue in fiscal 2025.

Is CTMX profitable?

CytomX Therapeutics, Inc. (CTMX) reported -$17.37M of net income, with a net margin of -22.8%.